Table 4. Lung development assessment.
| 21% O2 (n=6/gp) | 95% O2 (n=6/gp) | |||||||
|---|---|---|---|---|---|---|---|---|
| Vehicle | VA | RA | VARA | Vehicle | VA | RA | VARA | |
| MLI (μm) |
60.9 ± 7 |
57.8 ± 3 |
58.7 ± 9 |
62.4 ± 11 |
66.6 ± 3 |
63.0 ± 8 |
72.5 ± 9 |
58.2 ± 2 |
| RAC (septae) |
10.1 ± 4 |
9.3 ± 1.3 |
7.9 ± 0.4 |
9.4 ± 1.0 |
5.8 ± 3 |
7.2 ± 0.7 |
7.7 ± 1.8 |
7.9 ± 1.7 |
| SSC (per 50,000 μm2) |
4.4± 0.3 |
4.9± 0.3 |
4.7± 0.3 |
4.8± 0.3 |
4.3± 0.3 |
4.4± 0.3 |
4.2± 0.3 |
4.7± 0.3 |
Definitions of abbreviations: VA, Vitamin A; RA, retinoic acid; MLI, mean linear intercept; RAC, radial alveolar counts; SSC, secondary septal crests. MLI, RAC, and SSC showed no statistically significant differences between groups, except for a reduction in RAC in the 95% O2-Vehicle group compared to the 21% O2-Vehicle group.